Read by QxMD icon Read

Journal of Medical Economics

Roger Lee Mendoza
AIM: We review clinical evidence of therapeutic efficacy and effectiveness of omega-3 fatty acids (omega-3s) in keratoconjunctivitis sicca, colloquially known as dry eye disease. In doing so, we identify relevant literature to address the following questions: 1) What definitive guidance can clinical evidence offer eye physicians and their patients? 2) What aspects of omega-3 supplementation lack definitive evidence, and how might economic assessments help? METHODS: A targeted and systematic search strategy based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) was designed in this study for refereed clinical trials of omega-3s in dry eye treatment...
May 21, 2018: Journal of Medical Economics
Sayako Akiyama, Erika Tanaka, Olivier Cristeau, Yoshie Onishi, Yutaka Osuga
AIMS: Heavy menstrual bleeding (HMB) is a highly prevalent condition characterized by excessive menstrual blood loss and cramping that interferes with activities of daily life. The aim of our study was to investigate treatment patterns in HMB in Japan, and to assess healthcare resource utilization and costs among women newly diagnosed with the condition. MATERIALS AND METHODS: We retrospectively analysed health insurance data available in the Japan Medical Data Center (JMDC) database on women aged 18-49 years who were newly diagnosed with primary or secondary HMB...
May 17, 2018: Journal of Medical Economics
Michael S Broder, Beilei Cai, Eunice Chang, Tingjian Yan, Al B Benson
AIMS: To assess treatment adherence, healthcare resource utilization, and costs in GI NET patients initiating pharmacologic treatments in the US. METHODS: In 2 US commercial claims databases, patients ≥18 years with ≥1 inpatient or ≥2 outpatient GI NET claims within 12 months were identified. The first claim for pharmacologic treatments (e.g., somatostatin analogues [SSAs], cytotoxic chemotherapy [CC], targeted therapy [TT]) following diagnosis, between 7/1/2009-12/31/2014, was defined as the index date...
May 9, 2018: Journal of Medical Economics
J Bradford Rice, Alan G White, Michaela Johnson, Aneesha Wagh, Yimin Qin, Laura Bartels-Peculis, Gosia Ciepielewska, Winnie W Nelson
AIMS: Quantify healthcare resource use (HCRU) and costs associated with varying levels of corticosteroid exposure. MATERIALS AND METHODS: Patients with a diagnosis of selected autoimmune and inflammatory diseases between 1/1/2006 and 9/30/2015 ("study period") were selected from a de-identified, privately-insured claims database. Patients were stratified into four treatment cohorts based on the dosing and duration of continuous corticosteroid use following disease diagnosis: intermittent use with <60 days of corticosteroid use and ≥60 days of corticosteroid use with low (≤7...
May 9, 2018: Journal of Medical Economics
Parameswaran Hari, Huamao Mark Lin, Yanyan Zhu, Deborah Berg, Paul G Richardson, Philippe Moreau
AIMS: The aim of this analysis was to assess healthcare resource utilization in the pivotal phase 3 TOURMALINE-MM1 study of the oral proteasome inhibitor ixazomib or placebo plus lenalidomide and dexamethasone (Rd) in relapsed and/or refractory multiple myeloma (RRMM). METHODS: In this double-blind, placebo-controlled, randomized study (NCT01564537), 722 patients with RRMM following 1-3 prior lines of therapy received Rd plus ixazomib (ixazomib-Rd; N = 360) or matching placebo (placebo-Rd; N = 362) until disease progression or unacceptable toxicity...
May 9, 2018: Journal of Medical Economics
Xiaoyu Xi, Piaopiao Chen, Fan Yang, Yifan Yang, Lili Chen, Ningying Mao
OBJECTIVE: To evaluate the accessibility of essential medicines in China through a new system which integrated the structure, process, and effect of the National Essential Medicine Policy (NEMP). METHODS: A structural equation model was built to verify the reliability of the evaluation system. We utilized the Delphi method to obtain the structure and process index data, and used the WHO/HAI standard method for the effect index data to evaluate the NEMP. Six regions were selected for empirical analysis so that suggestions for optimization could be put forward...
May 9, 2018: Journal of Medical Economics
Nimita Arora, Koji Makino, Dominic Tilden, Kyriakos Lobotesis, Peter Mitchell, John Gillespie
AIMS: The goal of this study was to assess the cost-effectiveness of mechanical thrombectomy (MT) for acute ischemic stroke (AIS) from an Australian payer perspective. METHODS: We used a Markov model that employed a life-time time horizon, modelling patients from symptom onset of stroke until end of life. Clinical efficacy and safety data were taken from an individual patient level data (IPD) meta-analysis of clinical studies. The treatment effect of MT compared to usual care was measured by changes in modified Rankin Score (mRS)...
May 9, 2018: Journal of Medical Economics
Yiling Jiang, Xiaoqin Yang, Kazuko Taniguchi, Tanaz Petigara, Machiko Abe
OBJECTIVE: In Japan, the National Immunization Program (NIP) includes PPV23 as the primary vaccination for adults and catch-up cohorts. The Japanese Association for Infectious Diseases recommends revaccination for older adults who received primary vaccination ≥5 years earlier. The cost-effectiveness of adding revaccination and/or continuing catch-up vaccination in the NIP was evaluated from the public payer perspective in Japan. METHODS: The Markov model included five health states: no pneumococcal disease, invasive pneumococcal diseases (IPD), non-bacteremic pneumococcal pneumonia (NBPP), post-meningitis sequelae, and death...
May 3, 2018: Journal of Medical Economics
Mwangi J Murage, Amanda Anderson, Susan A Oliveria, Deborah Casso, Clement K Ojeh, Talia M Muram, Joseph F Merola, Andre B Araujo
AIMS: Describe healthcare resource utilization (HCRU) and costs among biologic-treated psoriasis patients in the US, overall and by disease severity. MATERIALS AND METHODS: IQVIA PharMetrics Plus administrative claims data were linked with Modernizing Medicine Data Services Electronic Health Record data and used to select adult psoriasis patients between 01-Apr-2010 and 31-Dec-2014. Eligible patients were classified by disease severity (mild, moderate, severe) using a hierarchy of available clinical measures...
May 2, 2018: Journal of Medical Economics
Shoshana R Daniel, John D McDermott, Cathy Le, Christine A Pierce, Michael A Ziskind, Lorie A Ellis
OBJECTIVES: To assess real-world infusion times for golimumab (GLM-IV) and infliximab (IFX) for rheumatoid arthritis (RA) patients and factors associated with treatment satisfaction. METHODS: An observational study assessed infusion time including: clinic visit duration, RA medication preparation and infusion time, and infusion process time. Satisfaction was assessed by a modified Treatment Satisfaction Questionnaire for Medication (patient) and study-specific questionnaires (patient and clinic personnel)...
May 2, 2018: Journal of Medical Economics
Michael W Drazer, Randy F Sweis
No abstract text is available yet for this article.
April 30, 2018: Journal of Medical Economics
Ryan Clark, Duygu Bozkaya, Mark Levenberg, Steven Faulkner, Timothy W Smith, Robert A Gerber
BACKGROUND: Atopic dermatitis (AD), a chronic inflammatory skin disease, is often treated with topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI). Crisaborole ointment is a nonsteroidal, phosphodiesterase 4 inhibitor for the treatment of mild to moderate AD. In December 2016, crisaborole was approved in the US for mild to moderate AD in patients ≥2 years of age. AIMS: To evaluate real-world utilization and cost of TCS and TCI in the US and estimate the budget impact of crisaborole over 2-years from a third-party payer perspective...
April 30, 2018: Journal of Medical Economics
Ziyi Lin, Xiuqin Rao, Zhijun Zhang, Jianwei Xuan
OBJECTIVES: In China, both human urinary kallindinogenase (HUK) and 3-n-butylphthalide (NBP) were recommended for clinical use to improve cerebral blood circulation during an acute ischemic stroke (AIS). The objective was to evaluate the economic value of HUK versus NBP for patients with AIS from a Chinese payer's perspective. METHODS: An economic evaluation based on data of patients who have been treated with either HUK (N = 488) or NBP (N = 885) from a prospective, phase IV, multicenter, clinical registry study (Chinese Acute Ischemic Stroke Treatment Outcome Registry, CASTOR) was conducted to analyze the cost and effectiveness of HUK versus NBP for AIS in China...
April 30, 2018: Journal of Medical Economics
Marita Zimmermann, Elisabeth Vodicka, Andrew Holman, Louis P Garrison
BACKGROUND: Autonomic nervous system (ANS) testing with heart rate variability (HRV) has been shown in early research to predict 52-week outcomes in rheumatoid arthritis (RA). HRV testing could be combined with putative ANS biologic pathways to improve treatment response for RA patients. We explored potential costs and health outcomes of introducing HRV testing into RA treatment, without and with ANS optimization. METHODS: A decision tree exploratory economic model compared HRV testing to standard care in moderate-to-severe biologic-eligible patients over a 10-year time horizon...
April 27, 2018: Journal of Medical Economics
Ellis J Neufeld, Robert F Sidonio, Ken O'Day, M Chris Runken, Kellie Meyer, Jeffrey Spears
BACKGROUND: Inhibitor development to factor VIII (FVIII) hemophilia therapy results in increased complications and substantial economic costs. The SIPPET study, the first randomized controlled trial to compare the immunogenicity of plasma-derived FVIII (pdFVIII)/von Willebrand factor (VWF) and recombinant-DNA-derived FVIII (rFVIII), demonstrated higher inhibitor rates in previously untreated patients (PUPs) treated with rFVIII than in PUPs treated with pdFVIII/VWF. OBJECTIVE: To quantify the economic impact of treating PUPs with pdFVIII/VWF versus rFVIII...
April 21, 2018: Journal of Medical Economics
Mark Nuijten, Agnieszka Marczewska, Krysmaru Araujo Torress, Bahareh Rasouli, Moreno Perugini
OBJECTIVES: Obesity is associated with high direct medical costs and indirect costs resulting from productivity loss. High prevalence of obesity generates a justified need to identify cost-effective weight loss approaches from a payer's perspective. Within the variety of weight management techniques, OPTIFAST® is a clinically recognized and scientifically proven total meal replacement Low Calorie Diet that provides meaningful results in terms of weight loss and reduction in comorbidities...
April 20, 2018: Journal of Medical Economics
Lisa M Hess, Zhanglin Lin Cui, Xiaohong Ivy Li, Ana B Oton, Scott Shortenhaus, Ian A Watson
BACKGROUND: Lung cancer is one of the most prevalent cancers in the United States. This study was designed to evaluate the actual drug wastage and cost to the healthcare system using patient-level retrospective observational electronic medical record (EMR) data from a cohort of lung cancer patients in the United States (US). METHODS: Data from the Flatiron Health advanced non-small cell lung cancer (NSCLC) cohort was used for this study. Drug administered amount (in mg) was used to determine an optimal set of available vial sizes to minimize waste...
April 19, 2018: Journal of Medical Economics
Ahmet Emre Eskazan
No abstract text is available yet for this article.
April 19, 2018: Journal of Medical Economics
Max Gill, Harmeet Chhabra, Mona Shah, Cyrus Zhu, Howard Lando, Felice Caldarella
AIMS: To analyze the association between provider, healthcare costs, and glycemic control for patients with diabetes mellitus (DM). MATERIALS AND METHODS: This cross-sectional study identified adults with type 1 or 2 DM (T1D, T2D) in the Optum database. The main independent variable was provider (endocrinologist or primary care). Regression analysis compared total medical and pharmacy costs, adjusting for health status and other patient differences, by provider...
April 19, 2018: Journal of Medical Economics
Shinichi Nishimura, Mutsuhiro Nakao
AIMS: We assessed the cost effectiveness of the orexin receptor antagonist suvorexant against zolpidem, the most widely used hypnotic benzodiazepine receptor agonist in Japan. To this end, a model was used that factored in insomnia and the risk for hip fractures, which have devastating effects on the elderly. METHODS: Data were derived from published papers. The target population was a virtual cohort of elderly patients (≥65 years) with insomnia residing in Japan...
April 18, 2018: Journal of Medical Economics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"